Syneron Medical Ltd. (ELOS) said its third-quarter net loss attributable to the company's shareholders was $5.55 million or $0.20 per share versus a profit of $2.19 million or $0.08 per share last year.
On a non-GAAP basis, excluding stock-based compensation expenses, net loss in the third quarter was $4.81 million or $0.17 per share, compared with a profit of $3.08 million or $0.11 per share in the third quarter of 2008.
Revenues for the third quarter of 2009 were $14.28 million, lower than $28.49 million in the comparable period. On average, 3 analysts polled by Thomson Reuters expected loss per share of $0.15 on revenues of $14.74 million for the quarter. Analysts' estimate typically excludes one-time items.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.